GfK Market Measures has established a dedicated business unit to provide insight for the rapidly growing oncology market, and appointed Bill Bowman, J.D., to lead it.
As Vice President of Oncology at GfK Market Measures, Bowman will be responsible for developing syndicated products for oncology and serve as a key in-house resource for custom research studies involving cancer therapies.
Bowman has 25 years’ experience in the pharmaceutical industry and more than 15 years in oncology, including time as a marketing researcher, product manager and sales rep with several major pharmaceutical manufacturers and supply-side firms. Most recently, he worked as an independent MR consultant working in partnership with oncology product teams for several major cancer therapies.
The company says it will develop syndicated oncology products to complement existing qual and quant custom research expertise in the area of oncology within the GfK U.S. Healthcare Companies, of which the company is a member.
‘This market is growing exponentially’ says Bowman, ‘due to major breakthroughs in understanding the molecular biology of cancer tumor types, which have resulted in an influx of targeted therapies including recent oral agents.’ A large number of products on the market and in development give pharmaceutical companies a challenged understanding market dynamics. Bowman says there is no product combining data on treatment patterns with in-depth analysis: ‘Clients must understand not only the science behind treatment regimens, but critically, how oncology patients are responding to them and this is the void GfK Market Measures hopes to fill in supporting this important area of disease management.’
The company is on the web at www.gfkmarketmeasures.com